No Data
No Data
FTAC Emerald Acquisition Faces Nasdaq Delisting and Strategic Transition
FTAC Emerald Acquisition Announces Extension of Deadline to Complete Business Combination
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted For Relutrigine In Dravet Syndrome; Praxis Plans To Initiate An All-DEE Trial (EMERALD), Inclusive Of Dravet Syndrome, In 1H2025
Canaccord Genuity Sticks to Their Buy Rating for Emerald Resources NL (EOGSF)
FTAC Emerald Acquisition Corp. Announces Change Of Ticker Symbol Of Its Common Stock To "FLDD" Commencing December 18, 2024
Express News | FTAC Emerald Acquisition Corp. Announces Special Meeting of Stockholders to Be Held on December 17, 2024